Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $61.1737 (-2.21%) ($60.4625 - $62.0815) on Wed. May. 17, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 0.74% (three month average) | RSI | 46 | Latest Price | $61.1737(-2.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV declines -0.2% a day on average for past five trading days. | Weekly Trend | ABBV declines -0.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(61%) VYM(49%) IVE(47%) IWD(47%) SPLV(47%) | Factors Impacting ABBV price | ABBV will decline at least -0.37% in a week (0% probabilities). VIXM(-17%) TLT(-13%) UUP(-10%) IGOV(-4%) IPO(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.37% (StdDev 0.74%) | Hourly BBV | 0 () | Intraday Trend | 0.6% | | | |
|
Resistance Level | $61.66 | 5 Day Moving Average | $61.81(-1.03%) | 10 Day Moving Average | $62.01(-1.35%) | 20 Day Moving Average | $61.66(-0.79%) | To recent high | -2.8% | To recent low | 7.6% | Market Cap | $107.928b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |